Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Alpha-protein kinase 3 (ALPK3) was recently identified as a candidate gene associated with hypertrophic cardiomyopathy (HCM). However, clinical data regarding carriers of ALPK3 variants are limited.
Objectives: To evaluate the prevalence of heterozygous ALPK3 variants in adult patients with HCM through whole-exome sequencing, and to elucidate the phenotypes of individuals harboring these variants.
Methods: Consecutive 575 patients diagnosed with HCM who underwent 3 Tesla cardiac magnetic resonance imaging (CMR) and whole exome sequencing genetic testing were recruited. Patients harboring ALPK3 rare missense variants (minor allele frequency < 0.0005) or truncating variants were considered genotype-positive.
Results: Among the 575 included patients (65.0% male; median age: 50 [40-61] years), 37 (6.43%) showed heterozygous ALPK3 variants. In comparison with sarcomere variant carriers, ALPK3 heterozygotes showed a higher prevalence of apical hypertrophy (59.5% vs. 20.2%, P < 0.001) and a lower fibrosis burden, with a 2-fold reduction in the incidence of extensive fibrosis (≥15% left ventricle [LV] mass: 8.1% vs. 14.7%, P < 0.001). Patients with single ALPK3 variants were more likely to present with apical HCM (ApHCM; 80.0% vs. 35.3%, P, 0.006) and show a lower extent of late gadolinium enhancement (LGE; 1.26 [0.00-5.77] % vs. 6.00 [3.63-8.50] %, P, 0.011) than those with both ALPK3 and sarcomere variants. CMR characteristics showed no significant differences between carriers with truncating and missense ALPK3 variants. Moreover, among patients with ApHCM, those with single ALPK3 variants were more likely to present with mixed ApHCM (87.5% vs. 55.2% vs. 14.3%, P < 0.05), a lower extent of LGE (0.67 [0-5.77] % vs. 6.32 [2.39-10.90] % vs. 3.32 [0.00-4.68] %, P < 0.05), and greater free-wall and apex LGE involvement (85.7% [six/7] vs. 41.6% [ten/24] vs. 50% [two/4]) than those with MYBPC3 or MYH7 variants.
Conclusion: The clinical phenotype of individuals harboring heterozygous ALPK3 variants showed distinct characteristics, characterized by apical hypertrophy, especially mixed apical hypertrophy, and a lower extent of fibrosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jocmr.2025.101930 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants.
Circulation
August 2025
Health in Code S.L., A Coruña, Spain; Spanish National Center for Cardiovascular Research (CNIC), Madrid, Spain.
Background: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder primarily linked to rare variants in sarcomere genes, though recently certain non-sarcomeric genes have emerged as important contributors. Non-Mendelian genetic variants with reproducible moderate effect sizes and low penetrance-intermediate-effect variants (IEVs)-, can play a crucial role in modulating disease expression. Understanding the clinical impact of IEVs is crucial to unravel HCM's complex genetic architecture.
View Article and Find Full Text PDFCardiac Phenotype Characterization at MRI in ALPK3 Associated Hypertrophic Cardiomyopathy.
J Cardiovasc Magn Reson
June 2025
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Cardiac Imaging and Target Therapy Lab, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. Electronic address:
Background: Alpha-protein kinase 3 (ALPK3) was recently identified as a candidate gene associated with hypertrophic cardiomyopathy (HCM). However, clinical data regarding carriers of ALPK3 variants are limited.
Objectives: To evaluate the prevalence of heterozygous ALPK3 variants in adult patients with HCM through whole-exome sequencing, and to elucidate the phenotypes of individuals harboring these variants.
ALPK3 Heterozygous Truncating Variants Cause Late-Onset Hypertrophic Cardiomyopathy With Frequent Apical Involvement and Apical Aneurysm.
Circ Genom Precis Med
August 2025
Cardiovascular Genetics Center (L.B., E.A.H., A.P., J.W., V.V., E.J.H.), University of California, San Francisco.
Whole-exome sequencing identifies novel truncating ALPK3 variants in a compound heterozygous state associated with pediatric hypertrophic cardiomyopathy and phenotypic heterogeneity.
Gene
September 2025
Department of Cardiology, Children's Hospital of Nanjing Medical University, Nanjing 210008, China. Electronic address:
Background: Pathogenic biallelic variants in ALPK3 are associated with recessively inherited early-onset and severe cardiomyopathies in children, often accompanied by extracardiac manifestations such as facial deformities and skeletal malformations. However, the number of reported cases remains limited. In this study, we report two additional pediatric patients with hypertrophic cardiomyopathy (HCM) having (likely) pathogenic heterozygous ALPK3 variants in a compound heterozygous state, together with a comprehensive review of the literature.
View Article and Find Full Text PDFUnravelling the Genotype of the Apical Variant of Hypertrophic Cardiomyopathy in a Swedish Cohort.
Genes (Basel)
April 2025
Department of Clinical Genetics, and Department of Biomedical and Clinical Sciences, Linköping University, 58185 Linköping, Sweden.
Background: Apical hypertrophic cardiomyopathy (ApHCM) is a distinct variant of hypertrophic cardiomyopathy (HCM). Few studies have focused on the genetic determinants of this subtype. We aimed to investigate the genetic basis of apical hypertrophy in a Swedish cohort.
View Article and Find Full Text PDF